Gambiaj.com – (Brescia, Italy) – The Gambia’s Medicines Control Agency (MCA) has entered into a strategic agreement with Italian multinational Antares Vision Group to enhance pharmaceutical traceability, regulatory oversight, and supply chain integrity. The deal, which spans several years, will introduce Antares Vision Group’s DIAMIND Government digital solutions to transform how medicines are monitored and regulated in the country.
The MCA selected Antares Vision Group, a global leader in track-and-trace systems and quality control, because of its proven expertise in guaranteeing product safety and transparency through integrated data management.
The collaboration is expected to deliver secure and efficient systems that will not only protect patients but also boost confidence in the national pharmaceutical sector.
Implementation of the project is scheduled to begin in the last quarter of 2025, with the MCA serving as the responsible body for driving the reforms.
By digitizing critical processes such as medicine registration, customs clearance, and inspections, the project promises to reduce the risks of counterfeit drugs, improve regulatory efficiency, and enhance patient safety.
To ensure the initiative is firmly grounded in the local context, Antares Vision Group has partnered with the Africa Agenda Network (AAN), a Gambian organization led by Saul Frazer. AAN will work to integrate the perspectives of local stakeholders and provide continuous on-the-ground support throughout implementation.
Antares Vision Group’s leadership has described the agreement as a milestone in advancing healthcare regulation in The Gambia. “Our solutions will ensure secure, transparent, and efficient pharmaceutical regulations, directly benefiting patients and healthcare stakeholders,” said Gianluca Mazzantini, the company’s CEO and general manager.
The agreement also aligns with The Gambia’s broader healthcare and development agenda. Over the next seven years, the project is expected to expand beyond pharmaceuticals to cover medical devices and other areas of healthcare regulation, with a vision of aligning the country’s health systems with regional and international best practices.
Through this partnership, The Gambia stands to gain not only stronger safeguards for patients but also improved regulatory credibility within ECOWAS and the wider global pharmaceutical industry.
